Incannex Secures $60M Financing To Drive Advances In Psychedelic And Cannabinoid Therapies
Incannex Secures $60M Financing To Drive Advances In Psychedelic And Cannabinoid Therapies
Incannex Healthcare Inc. (NASDAQ:IXHL), a cannabinoid and psychedelic medicine biotechnology company, announced Tuesday a significant financing agreement with Arena Investors, securing up to $60 million in funding. The deal includes $10 million in convertible notes and a $50 million equity line of credit (ELOC) with Arena Business Solutions (ABS), a related entity.
大麻素和迷幻药物生物技术公司Incannex Healthcare Inc.（纳斯达克股票代码：IXHL）周二宣布与Arena Investors达成一项重大融资协议，获得高达6000万美元的融资。该交易包括1000万美元的可转换票据和与关联实体Arena Business Solutions（ABS）的5000万美元股票信贷额度（ELOC）。
The financing will support the advancement of Incannex's clinical trials for its proprietary, synthetic cannabinoid and psychedelic-assisted therapeutics, targeting chronic conditions.
这笔资金将支持Incannex针对慢性病的专有合成大麻素和迷幻辅助疗法的临床试验的进展。
- Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.
- 每天在收件箱中免费获取Benzinga的独家分析以及有关大麻行业和市场的热门新闻。在这里订阅我们的时事通讯。如果你认真对待这项业务，就不能错过这个机会。
Key Trials Progressing, Says Incannex CEO
Incannex 首席执行官表示，关键试验正在进行中
Joel Latham, president and CEO of Incannex, expressed optimism about the partnership, highlighting its potential to drive key late-stage clinical milestones. "We look forward to updating investors on our progress, including progressing IHL-42X through Phase 2/3 trials for the treatment of obstructive sleep apnea, PsiGAD through a Phase 2 study for generalized anxiety disorder and IHL-675A through a Phase 2 trial for rheumatoid arthritis," Latham stated in a press release.
Incannex总裁兼首席执行官乔尔·莱瑟姆对该合作伙伴关系表示乐观，强调其有可能推动关键的后期临床里程碑。莱瑟姆在一份新闻稿中表示：“我们期待向投资者通报我们的最新进展，包括将 IHL-42X 推进治疗阻塞性睡眠呼吸暂停的2/3期试验，将psIGad推进广泛性焦虑症的2期研究，将 IHL-675A 推进类风湿关节炎的2期试验。”
Read Also: Psilocybin Drug By Psilera Could Treat Frontotemporal Dementia Without Psychoactive Effects
另请阅读：Psilera的psilocybin药物可以在没有精神活性作用的情况下治疗额膜痴呆
Incannex Financing Aligned With Strategic Goals
Incannex 融资与战略目标一致
Upon closing, Incannex will receive an initial tranche of $3.33 million, with the option to access two additional tranches totaling $6.67 million. The $50 million ELOC allows the company to issue and sell shares over the next 36 months, providing flexible capital as needed.
交易完成后，Incannex将获得333万澳元的首批资金，并可选择获得另外两笔总额为667万美元的资金。5000万美元的ELOC允许公司在未来36个月内发行和出售股票，并根据需要提供灵活的资本。
Furthermore, Incannex plans to use the funds to support clinical trials and general corporate purposes, with allocations aligned with the company's strategic priorities.
此外，Incannex计划将这笔资金用于支持临床试验和一般公司用途，其拨款与公司的战略优先事项保持一致。
IXHL Price Actio
IXHL's shares were trading 0.62% lower at $1.60 per share at the time of this writing around 11:45 AM ET Tuesday.
IXHL 价格走势
在撰写本文时，美国东部时间周二上午11点45分左右，IXHL的股价下跌0.62％，至每股1.60美元。
Related News
相关新闻
- Moxy: The Short, Intense Psychedelic High Sweeping The Globe
- Moxy：席卷全球的短暂而激烈的迷幻高潮
Photo: Courtesy of Hvoenok and GOR Photo on Shutterstock.
照片：由 Shutterstock 上的 Hvoenok 和 GOR Photo 提供。
